Assenagon Asset Management S.A. Invests $5.34 Million in Xenon Pharmaceuticals Inc. $XENE

Assenagon Asset Management S.A. acquired a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 119,186 shares of the biopharmaceutical company’s stock, valued at approximately $5,342,000. Assenagon Asset Management S.A. owned 0.15% of Xenon Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of XENE. Wellington Management Group LLP increased its holdings in Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after acquiring an additional 1,435,096 shares in the last quarter. Braidwell LP boosted its holdings in Xenon Pharmaceuticals by 33.0% in the 2nd quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock worth $112,837,000 after buying an additional 895,154 shares during the period. Commodore Capital LP increased its stake in Xenon Pharmaceuticals by 30.1% in the 2nd quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock worth $94,682,000 after buying an additional 700,000 shares in the last quarter. Vestal Point Capital LP raised its holdings in Xenon Pharmaceuticals by 53.8% during the second quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock valued at $62,600,000 after acquiring an additional 700,000 shares during the period. Finally, Holocene Advisors LP lifted its position in shares of Xenon Pharmaceuticals by 9.2% in the third quarter. Holocene Advisors LP now owns 1,976,553 shares of the biopharmaceutical company’s stock valued at $79,359,000 after acquiring an additional 167,078 shares in the last quarter. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on XENE. Stifel Nicolaus set a $66.00 target price on Xenon Pharmaceuticals in a research report on Tuesday, February 10th. Morgan Stanley set a $97.00 price target on Xenon Pharmaceuticals in a research note on Monday, March 9th. Jefferies Financial Group set a $100.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Wedbush lowered their target price on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating on the stock in a report on Monday, March 16th. Finally, Guggenheim restated a “buy” rating and set a $90.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $71.88.

Insider Transactions at Xenon Pharmaceuticals

In other news, insider Christopher John Kenney sold 1,410 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $77,874.30. Following the completion of the transaction, the insider owned 7,069 shares in the company, valued at approximately $390,420.87. The trade was a 16.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Andrea Difabio sold 1,342 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $74,118.66. Following the transaction, the insider directly owned 7,301 shares in the company, valued at approximately $403,234.23. This represents a 15.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 336,707 shares of company stock worth $19,622,565 in the last three months. Insiders own 4.07% of the company’s stock.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $54.48 on Friday. The company has a market cap of $4.53 billion, a price-to-earnings ratio of -12.50 and a beta of 0.91. Xenon Pharmaceuticals Inc. has a 1 year low of $26.74 and a 1 year high of $63.95. The stock’s 50 day simple moving average is $46.43 and its two-hundred day simple moving average is $43.07.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter in the prior year, the firm earned ($0.84) EPS. As a group, analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.